Colle Isabelle, Van Vlierberghe Hans
Department of Hepato-Gastroenterology, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium.
Acta Gastroenterol Belg. 2003 Apr-Jun;66(2):155-9.
Primary sclerosing cholangitis (PSC) leads to a progressive destruction of the intra- and extrahepatic bile ducts. The cause is unknown but genetic and immunological mechanisms may play a role. The median survival time from diagnosis to death is about 12 years. MRCP is almost equal to ERCP for diagnosing PSC and shows the typical localised or multifocal strictures and interfering segments of ectatic bile ducts. Liver histology can be helpful in making the diagnosis but is often unspecific and there is a large sampling variability. The treatment of PSC is disappointing. The combination of ursodeoxycholic acid with endoscopic dilatation is probably the best treatment. Patients with cirrhosis and/or recurrent cholangitis should be evaluated for liver transplantation as the outcome after liver transplantation is good, especially if there is no cholangio-carcinoma present and if the Child-Pugh score is not too high. There is also a need to treat the complication of PSC such as osteoporosis, cholangitis and the development of cholangiocarcinoma.
原发性硬化性胆管炎(PSC)会导致肝内和肝外胆管的进行性破坏。病因不明,但遗传和免疫机制可能起作用。从诊断到死亡的中位生存时间约为12年。磁共振胰胆管造影(MRCP)在诊断PSC方面几乎与内镜逆行胰胆管造影(ERCP)相当,可显示典型的局限性或多灶性狭窄以及扩张胆管的中断节段。肝脏组织学检查有助于诊断,但往往缺乏特异性,且存在较大的取材差异。PSC的治疗效果令人失望。熊去氧胆酸与内镜扩张联合使用可能是最佳治疗方法。对于肝硬化和/或复发性胆管炎患者,应评估其是否适合肝移植,因为肝移植后的效果良好,特别是在不存在胆管癌且Child-Pugh评分不太高的情况下。此外,还需要治疗PSC的并发症,如骨质疏松、胆管炎和胆管癌的发生。